Collaborations & Alliances

Oncolytics, Merck, Northwestern Conduct Phase II Combo Trial

Will further evaluate Keytruda and REOLYSIN in second line pancreatic cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oncolytics Biotech Inc., currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, will partner for an investigator sponsored study supported by Merck, Northwestern University and Oncolytics. This study is an extension of the previously reported Phase I study (REO 024) that will investigate pelareorep in combination with Merck’s anti-PD1 checkpoint inhibitor Keytruda, to treat second line pancreatic cancer patients. The study will enro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters